<DOC>
	<DOC>NCT02663518</DOC>
	<brief_summary>Multicenter, open-label, Phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies.</brief_summary>
	<brief_title>A Trial of TTI-621 for Patients With Hematologic Malignancies</brief_title>
	<detailed_description>This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies that will be conducted in 2 parts. In the dose Escalation Phase, subjects with lymphoma will be enrolled in sequential dose cohorts to receive TTI-621 to characterize safety, tolerability, pharmacokinetics, and the maximum-tolerated dose (MTD). In the Expansion Phase, subjects with a variety of hematologic malignancies will be treated at the optimal dose to further define safety and to characterize efficacy.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1. Histologically documented advanced lymphoma (escalation) advanced hematologic malignancies (expansion) with evaluable disease. 2. Adequate hematologic status 3. Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment. 4. Adequate coagulation function 5. Adequate hepatic function 6. Adequate renal function 1. Known central nervous system disease involvement. 2. Allogeneic transplant within 100 days prior to the planned start of treatment or subjects with active graftvshost disease with the exception of Grade 1 skin involvement. 3. History of hemolytic anemia or bleeding diathesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>